Developer docs
API playgroundTry for free, no card

Search company profiles

Diurnal Group

Full company profile

uuid0006o35

Namestring
Diurnal Group
Legal namestring
Immedica Pharma AB
Websiteurl
diurnal.co.uk
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCardiff, United Kingdom
HQ citystring
Cardiff
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
endocrine hormone drugs, hormone replacement therapy, adrenal insufficiency treatment, rare disease pharmaceuticals, specialty pharma manufacturing
Industry1 code
1Gender-Affirming Endocrine Care
CodeHLAKADAMPrimaryYes
Product category
Endocrine Therapeutics
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Diurnal Group is a pharmaceutical company that develops and commercializes therapeutic drugs targeting the endocrine hormone area, with a core focus on hormone replacement therapies for patients suffering from adrenal insufficiency and Addison's disease. The company creates targeted specialty pharmaceutical products addressing unmet medical needs in rare endocrine conditions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data does not contain specific product information for Diurnal Group. The provided sources contain market data about Addison's Disease Therapeutics (projected growth from USD 1.2 billion in 2024 to USD 2.5 billion by 2033) and information about Immedica Pharma's rare disease pharmaceutical portfolio, but no direct product details for Diurnal Group.

Product and service1 record
1Hormone Replacement Therapies for Adrenal Insufficiency
CategoryEndocrine Therapeutics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Shire (Takeda Rare Diseases)
TypeBroad incumbent
Description

Shire was the global leader in rare disease specialty pharma before its acquisition by Takeda, with an endocrinology portfolio that overlaps Diurnal's adrenal franchise. Comparable as a rare-disease commercial platform pursuing orphan endocrinology indications at scale.

2HRA Pharma
TypeDirect peer
Description

HRA Pharma is the most direct peer — a specialty pharma commercializing Plenadren (modified-release hydrocortisone) and other adrenal insufficiency therapies. It competes head-to-head with Diurnal's hormone replacement franchise for the same Addison's disease patient population and prescribing specialists.

3Alexion (AstraZeneca Rare Disease)
TypeBroad incumbent
Description

Alexion pioneered the rare disease orphan commercial model and is now AstraZeneca's rare disease unit. Comparable as the blueprint for building a global orphan endocrinology/multi-indication franchise with premium pricing and specialist distribution.

4Amryt Pharma (now Chiesi)
TypeEmerging player
Description

Amryt was a European-focused rare disease commercializer acquired by Chiesi. Comparable as a small specialty platform that scaled rare endocrine and metabolic assets via focused European distribution — analogous to Diurnal's path post-Immedica integration.

5Corcept Therapeutics
TypeDirect peer
Description

Corcept is a US specialty endocrine pharma commercializing Korlym (mifepristone) for Cushing's syndrome — a directly comparable endocrinology franchise addressing adrenal hyperfunction. It shares Diurnal's specialist-only physician targeting and orphan pricing model.

6Recordati Rare Diseases
TypeBroad incumbent
Description

Recordati operates a dedicated rare disease business unit that commercializes orphan therapies across Europe. It is comparable as a European-centered platform with the regulatory and market access infrastructure required to scale Diurnal-style endocrine assets.

7Neurocrine Biosciences
TypeBroad incumbent
Description

Neurocrine is a mid-cap specialty pharma with a growing endocrinology franchise (Cushing's and congenital adrenal hyperplasia). Comparable as a specialist-focused company building differentiated endocrine assets for rare indications.

8Tetralogic Pharmaceuticals / Sterling Pharma Solutions (endocrine CDMO peers)
TypeOthers
Description

Sterling is included as an OTHERS-level peer as a contract manufacturer supporting small endocrine pharma companies. Comparable indirectly through the steroid hormone API/formulation capabilities Diurnal would rely on to produce hydrocortisone-based products.

9Swedish Orphan Biovitrum (Sobi)
TypeBroad incumbent
Description

Sobi is a Sweden-headquartered rare disease specialty pharma with European commercial reach similar to Immedica. Its focus on rare endocrinology and metabolic conditions makes it a structurally comparable commercialization platform for Diurnal-type assets.

10Crinetics Pharmaceuticals
TypeEmerging player
Description

Crinetics is a clinical-stage endocrinology specialist developing novel therapies for rare endocrine disorders including Cushing's syndrome and acromegaly. It is comparable as a developer of differentiated rare endocrine therapies targeting the same specialist prescriber base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diurnal Group

Endocrine Therapeuticsdiurnal.co.uk

Diurnal Group firmographics

Firmographics
Name
Diurnal Group
Legal name
Immedica Pharma AB
Website
https://diurnal.co.uk
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Diurnal Group industry classification

Industry
Product category
Endocrine Therapeutics
akta.pro primary industry
Gender-Affirming Endocrine Care (HLAKADAM)

Keywords

  • Endocrine hormone drugs
  • Hormone replacement therapy
  • Adrenal insufficiency treatment
  • Rare disease pharmaceuticals
  • Specialty pharma manufacturing

Where Diurnal Group is headquartered

Location

Headquarters

HQ city
Cardiff
HQ country
United Kingdom
HQ region
Europe

Markets served

Diurnal Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Diurnal Group product offering

Product offering

Core offering

Diurnal Group is a pharmaceutical company that develops and commercializes therapeutic drugs targeting the endocrine hormone area, with a core focus on hormone replacement therapies for patients suffering from adrenal insufficiency and Addison's disease. The company creates targeted specialty pharmaceutical products addressing unmet medical needs in rare endocrine conditions.

Product overview

The source data does not contain specific product information for Diurnal Group. The provided sources contain market data about Addison's Disease Therapeutics (projected growth from USD 1.2 billion in 2024 to USD 2.5 billion by 2033) and information about Immedica Pharma's rare disease pharmaceutical portfolio, but no direct product details for Diurnal Group.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hormone Replacement Therapies for Adrenal Insufficiency

Companies that use Diurnal Group

Customer profile

Segments1 record

Ideal customer profiles1 record

Diurnal Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Diurnal Group partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Diurnal Group competitors and assessment

Company assessment

Broad incumbents

  • Shire (Takeda Rare Diseases): Shire was the global leader in rare disease specialty pharma before its acquisition by Takeda, with an endocrinology portfolio that overlaps Diurnal's adrenal franchise. Comparable as a rare-disease commercial platform pursuing orphan endocrinology indications at scale.
  • Alexion (AstraZeneca Rare Disease): Alexion pioneered the rare disease orphan commercial model and is now AstraZeneca's rare disease unit. Comparable as the blueprint for building a global orphan endocrinology/multi-indication franchise with premium pricing and specialist distribution.
  • Recordati Rare Diseases: Recordati operates a dedicated rare disease business unit that commercializes orphan therapies across Europe. It is comparable as a European-centered platform with the regulatory and market access infrastructure required to scale Diurnal-style endocrine assets.
  • Neurocrine Biosciences: Neurocrine is a mid-cap specialty pharma with a growing endocrinology franchise (Cushing's and congenital adrenal hyperplasia). Comparable as a specialist-focused company building differentiated endocrine assets for rare indications.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a Sweden-headquartered rare disease specialty pharma with European commercial reach similar to Immedica. Its focus on rare endocrinology and metabolic conditions makes it a structurally comparable commercialization platform for Diurnal-type assets.

Direct peers

  • HRA Pharma: HRA Pharma is the most direct peer — a specialty pharma commercializing Plenadren (modified-release hydrocortisone) and other adrenal insufficiency therapies. It competes head-to-head with Diurnal's hormone replacement franchise for the same Addison's disease patient population and prescribing specialists.
  • Corcept Therapeutics: Corcept is a US specialty endocrine pharma commercializing Korlym (mifepristone) for Cushing's syndrome — a directly comparable endocrinology franchise addressing adrenal hyperfunction. It shares Diurnal's specialist-only physician targeting and orphan pricing model.

Emerging players

  • Amryt Pharma (now Chiesi): Amryt was a European-focused rare disease commercializer acquired by Chiesi. Comparable as a small specialty platform that scaled rare endocrine and metabolic assets via focused European distribution — analogous to Diurnal's path post-Immedica integration.
  • Crinetics Pharmaceuticals: Crinetics is a clinical-stage endocrinology specialist developing novel therapies for rare endocrine disorders including Cushing's syndrome and acromegaly. It is comparable as a developer of differentiated rare endocrine therapies targeting the same specialist prescriber base.

Others

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Diurnal Group social profiles

Digital presence

Diurnal Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diurnal Group leadership team

Management profile

Number of profiles

Profiles3 records

Diurnal Group funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diurnal Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diurnal Group

What does Diurnal Group do?

Diurnal Group is a pharmaceutical company that develops and commercializes therapeutic drugs targeting the endocrine hormone area, with a core focus on hormone replacement therapies for patients suffering from adrenal insufficiency and Addison's disease. The company creates targeted specialty pharmaceutical products addressing unmet medical needs in rare endocrine conditions.

Is Diurnal Group a public or private company?

Diurnal Group is a private company. It is classified as corporate owned and is currently operating.

When was Diurnal Group founded?

Diurnal Group was founded in 2004. It employs 11 to 50 people.

Where is Diurnal Group based?

Diurnal Group is headquartered in Cardiff, United Kingdom, in the Europe region.

Who are Diurnal Group's main competitors?

Broad incumbents on record are Shire (Takeda Rare Diseases), Alexion (AstraZeneca Rare Disease), Recordati Rare Diseases, Neurocrine Biosciences and Swedish Orphan Biovitrum (Sobi). Direct peers are HRA Pharma and Corcept Therapeutics. Emerging players are Amryt Pharma (now Chiesi) and Crinetics Pharmaceuticals. Tetralogic Pharmaceuticals / Sterling Pharma Solutions (endocrine CDMO peers) is listed as an others.

Does Diurnal Group have an API?

No public API is recorded for Diurnal Group.

What industry is Diurnal Group in?

Diurnal Group's product category is Endocrine Therapeutics. Its primary akta.pro industry code is HLAKADAM, Gender-Affirming Endocrine Care.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024Neurocrine Biosciences and its subsidiary Diurnal Ltd. presented Phase 3 CAHtalyst trial data for crinecerfont at ENDO 2024, with results published in the New England Journal of Medicine showing 63% of adults and 29.9% of pediatric patients achieved reduction in glucocorticoid dosing to physiologic range while maintaining androgen control, compared with 18% and 0% on placebo respectively. The company also presented real-world data from the CAHtalog Registry demonstrating high rates of comorbidities associated with current supraphysiologic glucocorticoid dosing in CAH patients. New Drug Applications for crinecerfont were submitted to the FDA in April 2024 for both pediatric and adult populations.PR NewswireNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENNeurocrine Biosciences announced it will present key Phase 3 clinical data from its CAHtalyst registrational studies of crinecerfont in pediatric and adult patients with classic congenital adrenal hyperplasia, along with modified-release hydrocortisone study data, at the Endocrine Society Annual Meeting (ENDO 2024) in Boston, June 1-4. Data from both CAHtalyst studies supported two New Drug Application submissions to the U.S. Food and Drug Administration in April 2024. The company acquired Diurnal Group plc in November 2022, which had developed the modified-release hydrocortisone product EFMODY® that received marketing authorization in Great Britain and the European Union.MarketScreenerNeurocrine Biosciences, Inc. completed the acquisition of Diurnal Group plc from Diurnal Directors, IP Group Plc, Polar Capital Holdings plc, Development Bank of Wales Plc, Amati Global Investors Ltd.Neurocrine Biosciences, Inc. completed the acquisition of Diurnal Group plc from various shareholders including IP Group Plc and Polar Capital Holdings plc. This acquisition signifies Neurocrine's strategic expansion in the life sciences sector.GlobeNewswireForm 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)Hargreave Hale Limited disclosed an opening position in Diurnal Group plc on 30 August 2022, holding 2,100,000 ordinary shares representing 1.235% of the company. No dealings were recorded, and the disclosure was made under Rule 8.3 of the Takeover Code.FiercePharmaAmid launch efforts, Neurocrine doles out £48M to acquire small UK biotech DiurnalNeurocrine Biosciences agreed to acquire London-based Diurnal Group for approximately $56.5 million to expand its clinical development and commercial capabilities in the U.K. The transaction, which is expected to close by late October or early November, remains pending shareholder approval despite recommendations from Diurnal's chairman.GlobeNewswireEton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLEEton Pharmaceuticals acquired Canadian rights to ALKINDI SPRINKLE from Diurnal Group plc. The company currently commercializes the product in the U.S. for pediatric adrenocortical insufficiency. The acquisition aims to expand its orphan drug portfolio.FinSMEsUK, Diurnal Receives £600,000 Investment from Fusion IP and Finance WalesDiurnal, a Sheffield-based early-stage company, received £600,000 from Fusion IP and Finance Wales. The funds will develop its drug-delivery approach for endocrine therapy and complete Phase I trials of Chronocort for adrenal insufficiency by H1 2010. Fusion IP will hold a 51.6% stake after the investment.